Newsbenzinga
Enliven Therapeutics Announces FDA Alignment On Phase 3 Relcobatinib Chronic Myeloid Leukemia Trial Design, Expects Start Before Year-End
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…